Skip to main content
SpringerLink
Log in

Oral Medications in Vitiligo

  • Chapter
  • First Online:
Melasma and Vitiligo in Brown Skin

  • 1353 Accesses

Abstract

  • Many treatment modalities have been tried in vitiligo which includes medical and surgical modalities.

  • Medical treatments can include both topical and systemic therapies.

  • Since the etiopathogenesis of vitiligo is complex and not yet fully understood, treatments are often used in conjunction to get the best possible therapeutic benefit.

  • Vitiligo is being increasingly identified as a systemic disease and thus oral medications continue to play an important role in its treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lahiri K. Evolution and evaluation of autologous mini punch grafting in vitiligo. Indian J Dermatol. 2009;54:159–67.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90–100.

    Article  PubMed  Google Scholar 

  3. Lotti T, Gori A, Zanieri F, Colucci R, Moretti S. Vitiligo: new and emerging treatments. Dermatol Ther. 2008;21(2):110–7.

    Article  PubMed  Google Scholar 

  4. Szczurko O, Boon HS. A systematic review of natural health product treatment for vitiligo. BMC Dermatol. 2008;8:2.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Handa S, Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol. 1999;26:653–7.

    Article  CAS  PubMed  Google Scholar 

  6. Kent G, Al-abadie M. Factors affecting responses on dermatology life quality index among vitiligo sufferers. Clin Exp Dermatol. 1996;21:330–3.

    Article  CAS  PubMed  Google Scholar 

  7. Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology life quality index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003;148:373–4.

    Article  CAS  PubMed  Google Scholar 

  8. Parsad D, Gupta S. Standard guidelines of care for vitiligo surgery. Indian J Dermatol Venereol Leprol. 2008;74(S1):37–45.

    Google Scholar 

  9. Ismail SA, Sayed DS, Abdelghani LN. Vitiligo management strategy in Jeddah, Saudi Arabia as reported by dermatologists and experienced by patients. J Dermatol Treat. 2014;25:205–11.

    Article  Google Scholar 

  10. Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: a comprehensive overview part II: treatment options and approach to treatment. J Am Acad Dermatol. 2011;65(3):493–514.

    Article  PubMed  Google Scholar 

  11. Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: a comprehensive overview: part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91.

    Article  PubMed  Google Scholar 

  12. Taieb A, Alomar A, Bohm M, Dell’anna ML, De Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5–19.

    Article  CAS  PubMed  Google Scholar 

  13. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigm Cell Melanoma Res. 2012;25(3):E1–13.

    Article  CAS  Google Scholar 

  14. Lotti T. Vitiligo: problems and solutions. Int J Immunopath Pharmacol Dermatol. 2002;13:325–8.

    Google Scholar 

  15. Taieb A, Piccardo M. Clinical practice: vitiligo. N Engl J Med. 2009;360:160–9.

    Article  CAS  PubMed  Google Scholar 

  16. Buggiani G, Tsampau D, Hercogovà J, Rossi R, Brazzini B, Lotti T. Clinical efficacy of a novel topical formulation for vitiligo: compared evaluation of different treatment modalities in 149 patients. Dermatol Ther. 2012;25(5):472–6.

    Article  PubMed  Google Scholar 

  17. Kathuria S, Khaitan BK, Ramam M, Sharma VK. Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J Dermatol Venereol Leprol. 2012;78(1):68–73.

    Article  PubMed  Google Scholar 

  18. Lahiri K. Stability in vitiligo? What’s that? J Cutan Aesthet Surg. 2009;2(1):38–40.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Lahiri K, Malakar S. The concept of stability of vitiligo: a reappraisal. Indian J Dermatol. 2012;57:83–9.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Brosthoff H, Brosthoff J. Vitiligo and steroids. Lancet. 1978;2:688.

    Article  Google Scholar 

  21. Thomas PS. Prednisolone causing amelioration of both vitiligo and chronic active hepatitis. Br J Hosp Med. 1978;38:464.

    Google Scholar 

  22. Pasricha JS, Seetharam KA, Dashore A. Evaluation of five different regimens for the treatment of vitiligo. Indian J Dermatol Venereol Leprol. 1989;55:18–21.

    CAS  PubMed  Google Scholar 

  23. Gupta R. Causes of vitiligo. In: Gupta R, editor. Leucoderma (vitiligo). 1st ed. New Delhi: Atlantic Publishers and Distributors; 2007. p. 20–40.

    Google Scholar 

  24. Rath N, Kar HK, Sabhnani S. An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrowband UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol. 2008;74:357–60.

    Article  PubMed  Google Scholar 

  25. Gupta RR. Modified oral mini pulse steroid therapy in unstable vitiligo: a novel once a week regimen. Presented at 29th Annual Conference of IADVL; 2001. Unpublished.

    Google Scholar 

  26. Imran M. Childhood vitiligo: response to methylprednisolone OMP therapy and topical fluticasone preparation. Indian J Dermatol. 2010;54:124–7.

    Google Scholar 

  27. Pasricha JS, Khaitan BK. Oral minipulse therapy with betamethasone in vitiligo patients having extensive or fast spreading disease. Int J Dermatol. 2001;44:814–7.

    Google Scholar 

  28. Radakovik Fijan S, Furnissn-Friedl AM, Tanew A, Honigsman H. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 2001;44:814–7.

    Article  Google Scholar 

  29. Seiter S, Ugurel S, Tilgen W, Reinhold U. Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo. Int J Dermatol. 2000;39:624–7.

    Article  CAS  PubMed  Google Scholar 

  30. Nagata Y, Tanemura A, Ono E, Tanaka A, Kato K, Yamada M, Katayama I. Preliminary colorimetric assessment of progressive nonsegmental vitiligo under short-term intravenous methylprednisolone pulse therapy. J Cosm Dermatol Sci Appl. 2014;4:135–40.

    Google Scholar 

  31. Lee Y, Seo YJ, Lee JH, Park JK. High-dose prednisolone and psoralen ultraviolet a combination therapy in 36 patients with vitiligo. Clin Exp Dermatol. 2007;32:499–501.

    Article  CAS  PubMed  Google Scholar 

  32. Radmaneesh M, Saedi K. The efficacy of combined PUVA and low dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatol Treat. 2006;17:151–3.

    Article  Google Scholar 

  33. Sandra A, Pai S, Shenoi SD. Unstable vitiligo responding to methotrexate. Indian J Dermatol Venereol Leprol. 1998;64:309.

    CAS  PubMed  Google Scholar 

  34. Gokhale BB. Cyclophosphamide and vitiligo. Int J Dermatol. 1979;18:92.

    CAS  PubMed  Google Scholar 

  35. Gupta AK, Ellis CN, Nickoloff BJ, Nickoloff BJ, Goldfarb MT, Ho VC, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol. 1990;126:339–50.

    Article  CAS  PubMed  Google Scholar 

  36. Rigopoulos D, Gregorious S, Larios G, Larios G, Moustou E, Belayeva-Karatza E, Kalogeromitros D. Etanercept in the treatment of vitiligo. Dermatol. 2007;215:84–5.

    Article  Google Scholar 

  37. Smith DI, Heffernan MP. Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol. 2008;58:S50–1.

    Article  PubMed  Google Scholar 

  38. Ramı’rez-Herna’ndez M, Marras C, Martı’nez-Escribano JA. Infliximab- induced vitiligo. Dermatol. 2005;210:79–80.

    Article  Google Scholar 

  39. McKenna WB. Ammi majus Linn in the treatment of vitiligo. Scott Med J. 1957;2:69–70.

    Article  CAS  PubMed  Google Scholar 

  40. Benedetto AV. The psoralens. A historical perspective. Cutis. 1977;20:469–71.

    CAS  PubMed  Google Scholar 

  41. Fowlks WL. The chemistry of the psoralens. J Invest Dermatol. 1959;32:249–54.

    Article  CAS  PubMed  Google Scholar 

  42. El Mofty AM. A preliminary clinical report on the treatment of leucoderma with Ammi majus Linn. J Egypt Med Assoc. 1948;31:651–65.

    Google Scholar 

  43. Pathak MA, Fellman JH. Activating and fluorescent wave-lengths of furocoumarins: psoralens. Nature. 1960;185:382–3.

    Article  CAS  PubMed  Google Scholar 

  44. Buck HW, Magnus IA, Porter AD. The action spectrum of 8-methoxypsoralen for erythema in human skin: preliminary studies with a monochromator. Br J Dermatol. 1960;72:249–55.

    Article  CAS  PubMed  Google Scholar 

  45. Fulton Jr JE, Leyden J, Papa C. Treatment of vitiligo with topical methoxsalen and blacklite. Arch Dermatol. 1969;100:224–9.

    Article  PubMed  Google Scholar 

  46. Bouattour H, Chaabouni M. Comparative analytical study of the effects of psoralens in vitiligo (findings in 70 patients) (author’s transl). Ann Dermatol Venereol. 1978;105:507–10.

    CAS  PubMed  Google Scholar 

  47. Sharma VK, Jerajani HR, Srinivas HR, Kanwar AJ, Premalatha S, Sengupta SR, et al. Guidelines for medical management of vitiligo. In: Sharma VK, editor. IADVL therapeutic guidelines: guidelines for vitiligo, Stevens Johnson Syndrome-Toxic Epidermal Necrolysis and psoriasis. 1st ed. New Delhi: IADVL; 2009. p. 1–72.

    Google Scholar 

  48. Morison WL, Baugham RD, Day RM, Forbes PD, Hoenigsmann H, Krueger GG, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol. 1998;134:595–8.

    CAS  PubMed  Google Scholar 

  49. Grimes PE, Minus HR, Chakrabarti SG, Enterline J, Halder R, Gough JE, et al. Determination of optimal topical photochemotherapy for vitiligo. J Am Acad Dermatol. 1982;7:771–8.

    Article  CAS  PubMed  Google Scholar 

  50. El Mofty M, Mostafa W, Esmat S, Youssef R, Azzam O, Hunter N, et al. Narrow band ultraviolet B 311 nm in the treatment of vitiligo: two right-left comparison studies. Photodermatol Photoimmunol Photomed. 2006;22:6–11.

    Article  PubMed  Google Scholar 

  51. Bhatnagar A, Kanwar AJ, Parsad D, De D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol. 2007;21:638–42.

    Article  CAS  PubMed  Google Scholar 

  52. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol. 1997;133:1525–8.

    Article  CAS  PubMed  Google Scholar 

  53. Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen–UV-A therapy vs narrowband–UV-B therapy. Arch Dermatol. 2007;143:578–84.

    Article  CAS  PubMed  Google Scholar 

  54. Kwok YK, Anstey AV, Hawk JL. Psoralen photochemotherapy (PUVA) is only moderately effective in widespread vitiligo: a 10-year retrospective study. Clin Exp Dermatol. 2002;27:104–10.

    Article  CAS  PubMed  Google Scholar 

  55. British Photodermatology Group. An appraisal guideline for PUVA. Br J Dermatol. 1994;130:246–55.

    Article  Google Scholar 

  56. Ortel B, Tanew A, Honigsmann H. Treatment of vitiligo with khellin and ultraviolet A. J Am Acad Dermatol. 1988;18:693–701.

    Article  CAS  PubMed  Google Scholar 

  57. Orecchia G, Perfetti L. Photochemotherapy with topical khellin and sunlight in vitiligo. Dermatol. 1992;184:120–3.

    Article  CAS  Google Scholar 

  58. Dell’Anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigm Cell Res. 2006;19:406–11.

    Article  Google Scholar 

  59. Picardo M, Dell’Anna ML. Vitamins and antioxidants: topical and systemic. In: Picardo M, Taieb A, editors. Vitiligo. Berlin: Springer; 2010. p. 369–74.

    Chapter  Google Scholar 

  60. Akyol M, Celik VK, Ozcelik S, Polat M, Marufihah M, Atalay A. The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA. Eur J Dermatol. 2002;12:24–6.

    CAS  PubMed  Google Scholar 

  61. Dell’Anna ML, Mastrofrancesco A, Sala R, Venturini M, Ottaviani M, Vidolin AP, et al. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol. 2007;32:631–6.

    Article  PubMed  Google Scholar 

  62. Middelkamp-Hup MA, Bos JD, Riuz-Diaz F, Gonzalez S, Westerhof W. Treatment of vitiligo vulgaris with narrow band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo controlled study. J Eur Acad Dermatol Venereol. 2007;21:942–50.

    Article  CAS  PubMed  Google Scholar 

  63. Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. 2002;28:285–7.

    Article  Google Scholar 

  64. Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for the treatment of vitiligo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med. 2011;11:21.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Trompezinski S, Bonneville M, Pernet I, Denis A, Schmitt D, Viac J. Gingko biloba extract reduces VEGF and CXCL-8/IL-8 levels in keratinocytes with cumulative effect with epigallocatechin-3-gallate. Arch Dermatol Res. 2010;302(3):183–9.

    Article  PubMed  Google Scholar 

  66. Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with Ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. J Gen Intern Med. 2005;20(7):657–61.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Cohen BE, Elbuluk N, Mu EW, Orlow SJ. Alternative systemic treatments for vitiligo: a review. Am J Clin Dermatol. 2015;16(6):463–74.

    Google Scholar 

  68. Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol. 2012;132(7):1869–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Spritz RA. Recent progress in the genetics of generalized vitiligo. J Genet Genomics. 2011;38(7):271–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Spritz RA. Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid. 2010;20(7):745–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Egli F, Walter R. Images in clinical medicine. Vitiligo and pernicious anemia. N Engl J Med. 2004;350(26):2698.

    Article  CAS  PubMed  Google Scholar 

  72. Schallreuter KU, Chavan B, Rokos H, Hibberts N, Panske A, Wood JM. Decreased phenylalanine uptake and turnover in patients with vitiligo. Mol Genet Metab. 2005;86(S1):S27–33.

    Article  CAS  PubMed  Google Scholar 

  73. Schallreuter KU, Zschiesche M, Moore J, Panske A, Hibberts NA, Herrmann FH, et al. In vivo evidence for compromised phenylalanine metabolism in vitiligo. Biochem Biophys Res Commun. 1998;243(2):395–9.

    Article  CAS  PubMed  Google Scholar 

  74. Antoniou C, Schulpis H, Michas T, Katsambas A, Frajis N, Tsagaraki S, et al. Vitiligo therapy with oral and topical phenylalanine with UVA exposure. Int J Dermatol. 1989;28(8):545–7.

    Article  CAS  PubMed  Google Scholar 

  75. Ryan WL, Carver MJ. Inhibition of antibody synthesis by L-phenylalanine. Science. 1964;143(3605):479–80.

    Article  CAS  PubMed  Google Scholar 

  76. Siddiqui AH, Stolk LM, Bhaggoe R, Hu R, Schutgens RB, Westerhof W. L-phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatol. 1994;188(3):215–8.

    Article  CAS  Google Scholar 

  77. Cormane RH, Siddiqui AH, Westerhof W, Schutgens RB. Phenylalanine and UVA light for the treatment of vitiligo. Arch Dermatol Res. 1985;277(2):126–30.

    Article  CAS  PubMed  Google Scholar 

  78. Thiele B, Steigleder GK. Repigmentation treatment of vitiligo with L-phenylalanine and UVA irradiation [in German]. Z Hautkr. 1987;62(7):519–23.

    CAS  PubMed  Google Scholar 

  79. Karadag AS, Tutal E, Ertugrul DT, Akin KO, Bilgili SG. Serum holotranscobalamine, vitamin B12, folic acid and homocysteine levels in patients with vitiligo. Clin Exp Dermatol. 2012;37(1):62–4.

    Article  CAS  PubMed  Google Scholar 

  80. Shaker OG, El-Tahlawi SM. Is there a relationship between homocysteine and vitiligo? A pilot study. Br J Dermatol. 2008;159(3):720–4.

    CAS  PubMed  Google Scholar 

  81. Howitz J, Schwartz M. Vitiligo, achlorhydria, and pernicious anemia. Lancet. 1971;1(7713):1331–4.

    Article  CAS  PubMed  Google Scholar 

  82. Sabry HHSJ, Hashim HM. Serum levels of homocysteine, vitamin B12, and folic acid in vitiligo. Egypt J Dermatol Venereol. 2014;34:65–9.

    Article  Google Scholar 

  83. Montes LF, Diaz ML, Lajous J, Garcia NJ. Folic acid and vitamin B12 in vitiligo: a nutritional approach. Cutis. 1992;50(1):39–42.

    CAS  PubMed  Google Scholar 

  84. Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol. 1997;77(6):460–2.

    CAS  PubMed  Google Scholar 

  85. Tjioe M, Gerritsen MJ, Juhlin L, van de Kerkhof PC. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol. 2002;82(5):369–72.

    Article  CAS  PubMed  Google Scholar 

  86. Singh S, Singh U, Pandey SS. Increased level of serum homocysteine in vitiligo. J Clin Lab Anal. 2011;25(2):110–2.

    Article  CAS  PubMed  Google Scholar 

  87. Shameer P, Prasad PV, Kaviarasan PK. Serum zinc level in vitiligo: a case control study. Indian J Dermatol Venereol Leprol. 2005;71(3):206–7.

    Article  CAS  PubMed  Google Scholar 

  88. Bagherani N, Yaghoobi R, Omidian M. Hypothesis: zinc can be effective in treatment of vitiligo. Indian J Dermatol. 2011;56(5):480–4.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Yaghoobi R, Omidian M, Bagherani N. Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial. BMC Dermatol. 2011;11:7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Parsad D, Kanwar AJ. Oral minocycline in the treatment of vitiligo—a preliminary study. Dermatol Ther. 2010;23:305–7.

    Article  PubMed  Google Scholar 

  91. Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010;62(6):937–41.

    Article  CAS  PubMed  Google Scholar 

  92. Sehrawat M, Arora TC, Chauhan A, Kar HK, Poonia A, Jairath V. Correlation of vitamin D levels with pigmentation in vitiligo patients treated with NBUVB therapy. ISRN Dermatol. 2014;3:1–6.

    Article  Google Scholar 

  93. Finamor DC, Sinigaglia-Coimbra R, Neves LC, Gutierrez M, Silva JJ, Torres LD, et al. A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis. Dermato Endocrinol. 2013;5:222–34.

    Article  Google Scholar 

  94. Batchelor JM, Tan W, Tour S, Yong A, Montgomery AA, Thomas KS. Validation of the vitiligo noticeability scale: a patient-reported outcome measure of vitiligo treatment success. Br J Dermatol. 2016;174(2):386–94.

    Google Scholar 

  95. Lahiri K. Punch grafting in vitiligo. Indian J Dermatol Venereol Leprol. 1998;64:310–1.

    CAS  PubMed  Google Scholar 

  96. Lahiri K, Malakar S, Sarma N, Banerjee U. Inducing repigmentation by regrafting and phototherapy (311 nm) in punch grafting failure cases of lip vitiligo: a pilot study. Indian J Dermatol Venereol Leprol. 2004;70:156–8.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Apollo Gleneagles Hospitals, WIZDERM, Greenwood Nook, Coral Isle-14 RB, 369/2 Purbachal, Kalikapur, EM Byepass, Kolkata, 700070, India

    Koushik Lahiri

  2. St. John’s Medical College & Hospital, Bangalore, Karnataka, India, 560034

    Samujjala Deb

Authors
  1. Koushik Lahiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samujjala Deb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koushik Lahiri .

Editor information

Editors and Affiliations

  1. Asian Hospital and Medical Center, Muntinlupa, Philippines

    Evangeline B. Handog

  2. Angeles University Foundation Medical Center, Pampanga, Philippines

    Maria Juliet Enriquez-Macarayo

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer India

About this chapter

Cite this chapter

Lahiri, K., Deb, S. (2017). Oral Medications in Vitiligo. In: Handog, E., Enriquez-Macarayo, M. (eds) Melasma and Vitiligo in Brown Skin. Springer, New Delhi. https://doi.org/10.1007/978-81-322-3664-1_27

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-3664-1_27

  • Published:

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-3662-7

  • Online ISBN: 978-81-322-3664-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation